CCHT’s service laboratory has medical laboratory licence no L05235 from The Health Board of Estonia.

CCHT tests:

beREADY®   an advanced molecular tool to evaluate endometrium and its readiness for embryo implantation

beREADY bases on patented TAC-Seq technology and indicates whether the endometrium has a receptive molecular profile at the time when it is expected to be perfectly matured and ready for embryo implantation.

PGT-A – Preimplantation Genetic Testing for Aneuploidies

PGT-A is a genetic analysis that evaluates embryo chromosome number prior to transfer in an IVF cycle. It allows to identify embryos that have extra or missing chromosomes known as aneuploidy. Correct chromosome number is essential for proper development of embryo as well as child further on.


NIPTIFY® Non-invasive prenatal testing

NIPTIFY test is the newest and most sensitive prenatal screening method of chromosomes. It assesses the risk of developing foetal chromosomal abnormalities from the 10th week of gestation.The test assesses whether there is a risk that the number of copies of chromosomes 13 (Patau syndrome), 18 (Edwards syndrome), and 21 (Down syndrome) is different from the usual number of copies (two). The test can also determine the sex of the foetus.
For the analysis up to 10 ml venous blood are collected from the patient. NIPTiFY decreases need for invasive procedures that are and possibly dangerous.
Fertify® Evidence-based genetic test

Based on proprietary risk-assessment algorithm it predicts female fertility and age-related infertility. It has several advantages over conventional markers, as it can be used by young women who do not show remarkable changes in hormone dynamics or have no information on their mother’s menopausal age.

  • It is suitable for women using hormonal contraceptives
  • it is non-invasive, discreet and can disclose information for timely action
  • it can be performed once in a lifetime